Conference Coverage

Novel hemorrhagic stroke therapy bests medical management

Publish date: February 11, 2013

 

AT THE INTERNATIONAL STROKE CONFERENCE

The MISTIE trial was funded by the National Institute of Neurological Disorders and Stroke. Dr. Hanley reported having no relevant financial conflicts.

b.jancin@elsevier.com

Pages

Recommended Reading

FDA makes dabigatran contraindicated for mechanical valves
MDedge Cardiology
FDA approves apixaban for nonvalvular atrial fibrillation population
MDedge Cardiology
PFOs raise stroke risk from ICDs, pacemakers
MDedge Cardiology
Anticoagulant dabigatran ups the required dose of heparin
MDedge Cardiology
New AHA/ASA stroke guidelines stress rtPA, telemedicine
MDedge Cardiology
Depressed stroke survivors at increased risk of death
MDedge Cardiology
Endovascular stroke treatments add nothing beyond IV TPA
MDedge Cardiology
No benefit of endovascular therapy added to TPA for stroke
MDedge Cardiology
VIDEO: Marijuana may raise stroke risk
MDedge Cardiology
'Target: Stroke' improves door-to-needle TPA times
MDedge Cardiology